Pin Zhang

6PUBLICATIONS
16CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Pharmacogenomics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Aug 07, 2026
Overall Survival With Pyrotinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer: A Single-Center Pooled Analysis.

|Dec 24, 2025
Trastuzumab and pertuzumab plus carboplatin-based neoadjuvant therapy for HER2-positive breast cancer: a prospective cohort study with integrated genomic and transcriptomic biomarker analysis.

Xiaoyan Qian, Xi Chen, Min Xiao

|Jul 21, 2025
Pathologic complete response after neoadjuvant chemotherapy for HER-2 negative breast cancer with HRR mutation.

Xi Chen, Lei Ji, Ying Fan

|Jun 26, 2024
Low-dose pegylated recombinant human granulocyte-colony stimulating factor as hematopoietic support for adjuvant chemotherapy in Chinese patients with breast cancer: An open-label, randomized, non-inferiority trial.

Sheng Yang, Shan-Shan Chen, Chang-Gong Zhang

|Jun 20, 2023
Safety, Tolerability, and Pharmacokinetics of Senaparib, a Novel PARP1/2 Inhibitor, in Chinese Patients With Advanced Solid Tumors: A Phase I Trial.

Junning Cao, Hongqian Guo, Dongmei Ji

|Apr 11, 2022
Survival outcomes for dose-dense paclitaxel plus carboplatin neoadjuvant vs standard adjuvant chemotherapy in stage II to III triple-negative breast cancer: A prospective cohort study with propensity-matched analysis.

Meng Xiu, Pin Zhang, Xiang Wang

Pageof 1

Frequent Collaborators

2 joint publications

Qiao Li

2 joint publications

Fei Ma

2 joint publications

Binghe Xu

2 joint publications

Xi Chen